selenic acid has been researched along with Epilepsy, Temporal Lobe in 2 studies
Selenic Acid: A strong dibasic acid with the molecular formula H2SeO4. Included under this heading is the acid form, and inorganic salts of dihydrogen selenium tetraoxide.
Epilepsy, Temporal Lobe: A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite many antiseizure medications (ASMs) being available, up to one-third of patients do not achieve seizure control." | 3.30 | Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol. ( Carney, P; Casillas-Espinosa, P; Churilov, L; Gillinder, L; Hovens, CM; Johns, H; Kwan, P; Lawn, N; MacPhail, S; Malpas, C; Nicolo, JP; O'Brien, TJ; Perucca, P; Reutens, D; Shultz, SR; Tailby, C; Velakoulis, D; Vivash, L; Wijayath, M, 2023) |
| "Although drugs are available to control epileptic seizures, these only provide symptomatic relief." | 1.91 | Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy. ( Anderson, A; Barlow, CK; Brady, RD; Braine, EL; Casillas-Espinosa, PM; Harutyunyan, A; Huang, C; Jones, NC; Lee, J; Li, C; Mychasiuk, R; O'Brien, TJ; Schittenhelm, RB; Shah, AD; Shultz, SR; Sun, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casillas-Espinosa, PM | 1 |
| Anderson, A | 1 |
| Harutyunyan, A | 1 |
| Li, C | 1 |
| Lee, J | 1 |
| Braine, EL | 1 |
| Brady, RD | 1 |
| Sun, M | 1 |
| Huang, C | 1 |
| Barlow, CK | 1 |
| Shah, AD | 1 |
| Schittenhelm, RB | 1 |
| Mychasiuk, R | 1 |
| Jones, NC | 1 |
| Shultz, SR | 2 |
| O'Brien, TJ | 2 |
| Vivash, L | 1 |
| Johns, H | 1 |
| Churilov, L | 1 |
| MacPhail, S | 1 |
| Casillas-Espinosa, P | 1 |
| Malpas, C | 1 |
| Tailby, C | 1 |
| Wijayath, M | 1 |
| Reutens, D | 1 |
| Gillinder, L | 1 |
| Perucca, P | 1 |
| Carney, P | 1 |
| Nicolo, JP | 1 |
| Lawn, N | 1 |
| Kwan, P | 1 |
| Velakoulis, D | 1 |
| Hovens, CM | 1 |
1 trial available for selenic acid and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol.
Topics: Adult; Animals; Clinical Trials, Phase II as Topic; Drug Resistant Epilepsy; Epilepsy, Temporal Lobe | 2023 |
1 other study available for selenic acid and Epilepsy, Temporal Lobe
| Article | Year |
|---|---|
Disease-modifying effects of sodium selenate in a model of drug-resistant, temporal lobe epilepsy.
Topics: Animals; Drug Resistant Epilepsy; Epilepsy; Epilepsy, Temporal Lobe; Rats; Rats, Wistar; Seizures; S | 2023 |